New PICCOLO trial analyses showed that mirvetuximab soravtansine achieved 52% response rates and 27-month overall survival in ...

WELL, AN ASSISTANT PROFESSOR AT THE UNIVERSITY OF NEW MEXICO HAS JUST RECEIVED A GRANT TO CONDUCT MORE RESEARCH ON THE ...

New research from UC Davis Comprehensive Cancer Center has uncovered an evolutionary change that may explain why certain ...

Obesity, a growing global epidemic, is identified as a significant, modifiable risk factor for ovarian cancer, a deadly ...

Ovarian cancer remains a significant global health challenge, often diagnosed at an advanced stage due to non-specific ...

AbbVie Inc. (NYSE:ABBV) is one of the undervalued S&P 500 stocks to buy according to hedge funds. On June 25, the “Elahere ...

Patients with ovarian clear cell carcinoma (OCCC) whose tumors have specific mutations in the PPP2R1A gene were found to have ...

Non-invasive epithelial tumors of the ovary that show abnormal cell growth but lack the capacity to invade surrounding ...

Patients with ovarian clear cell carcinoma (OCCC) whose tumors have specific mutations in the PPP2R1A gene were found to have improved survival following immunotherapy compared to patients without ...

ALBUQUERQUE, N.M. — A University of New Mexico study of the effectiveness of a new treatment for ovarian cancer has received a $30,000 grant from the American Cancer Society. The grant will ...

According to a new comprehensive report from The Insight Partners, the global ovarian cancer drugs market is observing ...

There's a long way to go when it comes to sex and gender equity in medicine, but engineers at The University of New Mexico hope to close the gap with ...